Combining c-Met and PARP1 inhibitors synergized to suppress the growth of breast cancer cells in vitro and lung cancer xenograft tumor models, which highlighted a treatment with a combination of c-Met and PARP inhibitors in patients bearing tumors with high c-Met expression. Here, MET is linked to lung carcinoma.